Search

Your search keyword '"Crom D"' showing total 2 results
Start Over Author "Crom D" Topic antineoplastic combined chemotherapy protocols
2 results on '"Crom D"'

1. Treatment of unresectable or metastatic osteosarcoma with cisplatin or cisplatin-doxorubicin.

Author

Pratt CB, Champion JE, Senzer N, Green AA, Rao B, Douglass E, Meyer WE, and Crom DB

Subjects
Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bone Neoplasms pathology, Bone Neoplasms secondary, Child, Chondrosarcoma drug therapy, Cisplatin administration & dosage, Cisplatin adverse effects, Doxorubicin administration & dosage, Histiocytoma, Benign Fibrous drug therapy, Humans, Lung Neoplasms drug therapy, Lung Neoplasms secondary, Nausea chemically induced, Osteosarcoma pathology, Osteosarcoma secondary, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Neoplasms drug therapy, Cisplatin therapeutic use, Osteosarcoma drug therapy
Abstract

Responses and toxicity after treatment with cisplatin and cisplatin-doxorubicin were compared in two groups of patients with unresectable or metastatic osteosarcoma. Complete or partial responses developed in 3 of 18 individuals treated with cisplatin, and in 5 of 19 after the two-drug combination. Hematologic and gastrointestinal complications were more frequent and severe in patients who received both agents. The combined use of cisplatin and doxorubicin is justified for patients with unresectable or metastatic osteosarcoma at diagnosis because of the potential therapeutic benefits for these individuals.

Published
1985
Full Text
View/download PDF

2. Cisplatin and doxorubicin for locally recurrent and metastatic childhood rhabdomyosarcoma.

Author

Pratt CB and Crom DB

Subjects
Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols adverse effects, Child, Child, Preschool, Cisplatin administration & dosage, Doxorubicin administration & dosage, Female, Humans, Male, Rhabdomyosarcoma secondary, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neoplasm Recurrence, Local drug therapy, Rhabdomyosarcoma drug therapy
Abstract

Five pediatric subjects, each of whom had been treated with multiple agents including doxorubicin, received cisplatin and doxorubicin following the development of locally recurrent or metastatic rhabdomyosarcoma. Although there was no definite evidence that the tumor of these individuals was resistant to doxorubicin, tumor responses developed in 3 of 5 patients. Additional trials of this combination in similar patients with primary or recurrent metastatic rhabdomyosarcoma are indicated.

Published
1984

Catalog

Books, media, physical & digital resources
See catalog results